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Objectives: The objectives of this study were to estimate the impact of recruitment source and 
outcome definition on the incidence of acute exacerbations of COPD (AECOPD) and explore 
possible predictors of AECOPD.
Patients and methods: During a 1-year follow-up, we performed a baseline visit and four 
telephone interviews of 81 COPD patients and 132 controls recruited from a population-based 
survey and 205 hospital-recruited COPD patients. Both a definition based on health care utiliza-
tion and a symptom-based definition of AECOPD were applied. For multivariate analyses, we 
chose a negative binomial regression model.
Results: COPD patients from the population- and hospital-based samples experienced on average 
0.4 utilization-defined and 2.9 symptom-defined versus 1.0 and 5.9 annual exacerbations, respec-
tively. The incidence rate ratios for utilization-defined AECOPD were 2.45 (95% CI 1.22–4.95), 
3.43 (95% CI 1.59–7.38), and 5.67 (95% CI 2.58–12.48) with Global Initiative on Obstructive 
Lung Disease spirometric stages II, III, and IV, respectively. The corresponding incidence rate 
ratios for the symptom-based definition were 3.08 (95% CI 1.96–4.84), 3.45 (95% CI 1.92–6.18), 
and 4.00 (95% CI 2.09–7.66). Maintenance therapy (regular long-acting muscarinic antagonists, 
long-acting beta-2 agonists, inhaled corticosteroids, or theophylline) also increased the risk of 
AECOPD with both exacerbation definitions (incidence rate ratios 1.65 and 1.73, respectively). The 
risk of AECOPD was 59%–78% higher in the hospital sample than in the population sample.
Conclusion: If externally valid conclusions are to be made regarding incidence and predictors 
of AECOPD, studies should be based on general population samples or adjustments should be 
made on account of a likely higher incidence in other samples. Likewise, the effect of different 
AECOPD definitions should be taken into consideration.
Keywords: COPD, exacerbations, general population, predictors
Introduction
Acute exacerbations of COPD (AECOPD) are associated with mortality and poorer 
quality of life, leading to higher consumption of health resources, and a more rapid 
decline in lung function compared to COPD patients without frequent exacerbations.1–3 
AECOPD pose a great burden to both patients and society.4
There is scarce knowledge on the incidence and predictors of COPD exacerbations 
in COPD patients from the general population. Estimates from previous studies have 
shown an AECOPD rate per person per year from 0.65 to 1.40.5–7 These estimates vary 
by exacerbation definitions. A study comparing health care utilization and symptom-
defined AECOPD observed higher incidence using the symptom-based definition.8 
The symptoms defining AECOPD are common, and even healthy individuals 
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experience them at times.5,9 Hence, if the symptom-based 
definition is to be used, inclusion of a control group is neces-
sary for adjustment of the baseline burden of these symptoms 
in the healthy population.
Most previous studies are done on selected populations 
without a plausible control group.1,3–6,8,10–13 Nevertheless, studies 
have indicated that exacerbation risk increases with higher 
age,6,7,10–13 a history of previous exacerbations,5–7,10,13,14 increas-
ing airflow obstruction,5,6,10–16 inflammatory biomarkers,13,17–20 
gastroesophageal reflux,16,21,22 depression,23,24 reduced quality 
of life,5,8,13 low body mass index (BMI), or weight loss,6,8,25 
in addition to chronic respiratory symptoms.7,11,15,26
Only two previous studies have genuine population-
based study samples. The PLATINO study used a symptom-
based definition of AECOPD in a general population,15 but 
it was retrospective, did not define a control group, and 
did not report utilization-based exacerbations. Based on 
the COPDGene sample, Bowler et al5 reported utilization-
defined exacerbations gathered by six-monthly telephone 
interviews, but they did not include a control group without 
airflow obstruction. Thus, to our knowledge, there is no 
study where two exacerbation definitions were applied 
to the same study population and where a control group 
was included.
Important treatment-related decisions are currently made 
based on studies using different definitions of AECOPD and 
based on samples that are not population based;3,6,14 thus, the 
effect of these choices needs to be estimated and the impact 
on predictors of exacerbations needs to be examined. The 
aims of this study were to estimate the incidence of AECOPD 
in the general population with two different exacerbation 
definitions, compare the results to a hospital-based COPD 
study sample, and explore predictors of AECOPD in both 
COPD study samples. We hypothesized that the population 
sample exacerbated less often than the hospital sample and 
that the symptom-based exacerbation definition resulted 
in a higher exacerbation rate compared to the health care 
utilization-based definition.
Methods
Our data were from the EconCOPD study, a 1-year prospec-
tive observational study conducted between March 2005 
and August 2006 at Haukeland University Hospital, Bergen, 
Norway. The study was approved by the Regional Committee 
for Medical and Health Research Ethics in Western Norway 
(REK Vest case number 252.04), and all participants provided 
written informed consent. Details on sampling procedures 
and data collection have previously been published.27
study population and design
EconCOPD recruited three groups of participants who 
went through the same study during the same time frame: 
COPD patients from Haukeland University Hospital’s 
COPD register and COPD cases and control subjects from 
a general population cohort. The population-based cases and 
controls were recruited from a follow-up examination of the 
Hordaland County Respiratory Health Survey in 2003–2004, 
a random and representative sample of the population in 
Hordaland County in 1985.28 COPD patients from the gen-
eral population sample who had received treatment at the 
University Hospital were only registered as participants in 
the population-based sample.
Participants were all current or former smokers 
of $2.5 pack-years and were at least 40 years old. The 
choice of using 2.5 pack-years as the lower limit for smoking 
exposure was made to exclude nontobacco-associated COPD 
cases.29 COPD was defined as a post-bronchodilator ratio of 
the forced expiratory volume in 1 second (FEV
1
) to the forced 
vital capacity ,0.70 and FEV
1
 ,80% predicted according 
to age, sex, and height.30 Postbronchodilator spirometry 
was performed according to American Thoracic Society 
standards.31 The control subjects had an FEV
1
/forced vital 
capacity ratio .0.70 and FEV
1
 .80% predicted. The latter 
group was included to be able to adjust for a baseline risk 
of having exacerbation-like symptoms or events in a general 
population without respiratory disease.
All included participants were interviewed at baseline 
concerning smoking habits, education and employment 
status, and comorbidities. They were all clinically assessed 
by the project physician (RG). At 12 weeks, 24 weeks, 
36 weeks, and 52 weeks, a follow-up interview was con-
ducted by telephone, gathering information on productivity 
losses, health care utilization, and exacerbations of respira-
tory symptoms. Follow-up by telephone was considered 
satisfactory as no biological measurements were needed, 
the interval between interviews was short, and telephone 
coverage was reliable in the area.32,33 Information on comor-
bidities was gathered by asking for conditions listed in the 
Charlson Comorbidity Index.34
Exacerbation definition
We defined a symptom-based AECOPD as an increase in 
two major symptoms (dyspnea, sputum volume, or sputum 
color) or one major and one minor symptom (cough, sore 
throat, nasal secretion, wheezing, or asthenia) for at least two 
consecutive days (modified Anthonisen criteria).35,36 A health 
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Incidence of COPD exacerbations: outcome definition and population
antibiotics or corticosteroids due to respiratory disease or by 
hospitalization due to respiratory disease.
statistical analyses
To test the distribution of characteristics across participant 
groups, we used parametric (t-test, analysis of variance) 
or nonparametric (χ2, Kruskal–Wallis) tests.
The frequency of exacerbations was skewed. Thus, 
we chose Kruskal–Wallis tests with ties and negative 
binomial regression for bivariate and multivariate analyses, 
respectively.37 For the latter, we first performed bivariate 
analyses of each possible predictor and included those that 
were significant with a P-value of ,0.10 in the final mul-
tivariate model. To estimate the effect of sampled popula-
tion, we pooled the population-based and hospital-recruited 
participants and adjusted for participant group as well as 
COPD severity (Global Initiative on Obstructive Lung 
Disease [GOLD]-defined FEV
1
 categories). We estimated 
regression models both for symptom-defined exacerba-
tions and exacerbations identified by health care utilization. 
The models included age, sex, smoking status, pack-years, 
educational level, FEV
1
% predicted, number of comorbid 
conditions, maintenance therapy (defined as regular use 
of long-acting muscarinic antagonists, long-acting beta-2 
agonists, inhaled corticosteroids, or theophylline), influenza 
vaccination, pneumococcal vaccination, oxygen therapy, 
and BMI. The incidence rate ratio for each predictor gives 
their associated relative risk of exacerbation, adjusting for 
the other predictors.
All analyses were performed using Stata SE 13.1 (Stata-
Corp LP, College Station, TX, USA).
Results
Characteristics
The characteristics and unadjusted exacerbation rates of each 
study group are shown in Table 1. Sex and smoking status did 
not vary between the participant groups, but differences were 
found for age, education, lung function, comorbidities, and 
being underweight (P,0.001). Nearly all hospital-recruited 
COPD patients received maintenance therapy for their COPD 
(80%), whereas a significantly lower percentage used main-
tenance therapy in both the population-based COPD sample 
and the control group (P,0.001). A similar pattern applied 
to vaccination status.
A population-recruited COPD patient had an average 
of 0.4 utilization-defined exacerbations per year and 
2.9 symptom-defined exacerbations per year. The respective 
numbers for COPD patients from the hospital register were 1.0 
utilization-defined exacerbations per year and 5.9 symptom-
defined exacerbations per year, while the participants in the 
control group had 0.1 and 0.7 exacerbations per year with the 
respective exacerbation definitions (Table 1). For all three 
groups, the resulting exacerbation rates were skewed, with 
a total of 349 (83%) and 264 (63%) participants having zero 
or one exacerbation per year with the utilization-based and 
the symptom-based definitions, respectively.
Bivariate analyses
In bivariate analyses, we found that receiving maintenance 
therapy was associated with a higher exacerbation rate. With 
the utilization-based definition, increased GOLD stage was 
related to increased exacerbation rate. We found no consistent 
pattern for age, sex, education, smoking status, BMI, or vac-
cination (Tables S1 and S2).
Multivariate analyses
Tables S3 and S4 show the results from the bivariate and 
multivariate negative binomial regression analyses, including 
all COPD patients defined by either of the two study samples, 
and the results are illustrated in Figure 1.
Applying the utilization-based exacerbation definition 
(Table S3), we found that the incidence rate ratio for COPD 
exacerbations was significantly higher in the hospital sample 
compared to the population sample, even after extensive 
adjustment for potential confounders. There were increas-
ingly higher exacerbation risks with increasing severity of 
COPD. Female sex and receiving maintenance therapy were 
also significantly associated with higher risk of exacerbation 
in the multivariate model. Applying the symptom-based 
exacerbation definition (Table S4), we found, with three 
exceptions, the same main predictors as with the utilization-
based definition. The exceptions were female sex that was not 
significantly associated with exacerbation risk, increasing age 
that was significantly associated with a lower exacerbation 
risk, and having undergone influenza vaccination that was 
significantly associated with a lower risk of exacerbation.
Discussion
We have shown that on average, a community-dwelling 
COPD patient had 0.4 utilization-based exacerbations 
per year, while COPD patients selected from a hospital 
register had one exacerbation per year (2.5 times more). 
The results for the symptom-based definition were 2.9 and 
5.9 exacerbations per year (2.0 times more), respectively, for 
the two groups. In multivariate regression analysis, belong-
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n 205 81 132 –
Male, n (%) 123 (60) 53 (65) 69 (52) 0.142
age (yrs), mean (sD) 67 (9.2) 63 (10.0) 57 (10.6) ,0.001
smoking status, n (%)
Current smoker 68 (33) 38 (47) 63 (48) 0.012
Former smoker 137 (67) 43 (53) 69 (52) –
Pack-years, mean (sD) 32.7 (31.0) 32.3 (35.6) 15.5 (12.3) ,0.001
educational level, n (%)
Primary 75 (37) 32 (40) 27 (20) ,0.001
secondary 100 (49) 30 (37) 63 (48) –
University 30 (15) 19 (23) 42 (32) –
FeV1% predicted, n (%)
$80 – – 132 (100) ,0.001
$50–,80 103 (50) 69 (85) – –
$30–,50 68 (33) 8 (10) – –
,30 34 (17) 4 (5) – –
Mean FeV1% predicted (sD) 47.7 (16.7) 64.9 (14.2) 95.4 (8.8) ,0.001
Median FeV1% predicted (IQr) 50.4 (26.8) 68.7 (16.7) 94.2 (10.1) ,0.001
Comorbid conditions
Mean (sD) 1.9 (1.8) 1.2 (1.5) 0.8 (1.0) ,0.001
Median (IQr) 1 (3) 1 (2) 0 (1.5) ,0.001
Resource-defined exacerbations
Mean (sD) 1.0 (1.2) 0.4 (0.9) 0.1 (0.4) ,0.001
Median (IQr) 1 (2) 0 (0) 0 (0) ,0.001
Symptom-defined exacerbations
Mean (sD) 5.9 (6.1) 2.9 (6.2) 0.7 (1.5) ,0.001
Median (IQr) 4 (8) 1 (3) 0 (1) ,0.001
Maintenance therapy, n (%) 164 (80) 31 (38) 2 (2) ,0.001
Undergone vaccination, n (%)
Influenza 146 (71) 28 (35) 15 (11) ,0.001
Pneumococcus 97 (47) 4 (5) 2 (2) ,0.001
Oxygen therapy, n (%) 19 (9) 0 0 ,0.001
BMI (m/kg2), n (%)
Underweight 14 (7) 3 (4) 1 (1) 0.026
normal range 80 (39) 30 (37) 58 (44) 0.543
Overweight 111 (54) 48 (59) 73 (55) 0.734
Abbreviations: yrs, years; sD, standard deviation; FeV1, forced expiratory volume in 1 second; IQr, interquartile range; BMI, body mass index.
increased relative risk of experiencing an exacerbation 
compared to the population sample. In both groups, there 
were increasingly higher exacerbation rates with increas-
ing COPD severity. By including control subjects, we have 
adjusted for the incidence of exacerbation-like events in 
subjects without respiratory disease.
This confirmed our hypothesis that COPD patients from 
a hospital register have more exacerbations than COPD 
patients found in the general population and, furthermore, 
that using a symptom-based definition results in a higher 
exacerbation rate than with a utilization-based definition.
The only population-based study that provides comparable 
data is the PLATINO study. It estimated an exacerbation-
rate of 0.58/person/yr with a symptom-based exacerbation 
definition.15 The study was retrospective with a longer 
Figure 1 Irrs for COPD exacerbations when using a utilization-based and 
symptom-based definition. 
Note: results from multivariate negative binomial regression models.
Abbreviations: Irr, incidence rate ratio; gen pop, general population; gOlD, 
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Incidence of COPD exacerbations: outcome definition and population
recollection period, and the subjects might have been more 
prone to recall bias. Bowler et al5 found an exacerbation rate 
of 0.65/person/yr for COPD patients using a utilization-based 
definition. They included all GOLD stages, including stage I. 
The results from the TORCH study, where the sample was 
from outpatient clinics and a utilization-based definition was 
applied, showed an annual exacerbation rate between 0.85 
and 1.13.6 In the study performed by Husebø et al,7 they used 
a utilization-based definition and found an annual exacerba-
tion rate per person to be 1.40 for their outpatient sample of 
COPD patients. Our results are in line with the results from 
the PLATINO study, but extend the previous knowledge 
on exacerbation rates and give enhanced understanding of 
the implications of how the selection of study samples and 
exacerbation definitions affect the results.
The independent predictors of increased exacerbation 
rates were belonging to the hospital sample, decreasing 
FEV
1
/increasing airflow limitation, female sex, and receiving 
maintenance therapy for the utilization-based definition. 
For the symptom definition, the same predictors were sig-
nificantly associated with higher exacerbation risk apart 
from female sex, which did not prove significant, and adding 
increasing age and influenza vaccination, which were associ-
ated with a lower risk if present.
It is a novel, but not surprising, finding that hospital sam-
ples gave higher exacerbation rates than population-based 
samples. The participants recruited from the hospital register 
can be expected to have more severe disease as seen in the 
newly published study by Müllerova et al13 and therefore to 
exacerbate more often. Müllerova et al found a hazard ratio 
for hospitalization due to AECOPD at 1.12 per 5% drop of 
FEV
1
% predicted, and those who did not exacerbate had a sig-
nificantly lower BODE (Body mass index, airflow Obstruc-
tion, Dyspnea and Exercise capacity) index. We think our 
analyses demonstrated that studies on AECOPD recruiting 
from outpatient or hospital samples are biased toward higher 
exacerbation rates as compared with a general population. 
This might be not only due to differences in airflow limita-
tion but also due to unidentified factors associated with the 
so-called frequent exacerbator phenotype.
The observed exacerbation risk associated with decreasing 
FEV
1
 has previously been seen by various authors.1,3,7,10,11,15,38 
As the airflow limitation increases, even minor influences from 
exacerbation-causing agents may lead to a worsening where a 
change in medication or even hospitalization is needed.
Whether female sex is truly associated with a greater 
risk of COPD exacerbations is an ongoing debate. It is 
not known if females perceive their symptoms differently, 
seek medical aid more frequently, or are genuinely more 
prone to exacerbations than men.39,40 Studies have shown 
both biological and cultural associations between sex and 
respiratory disease.41 We found that female sex was only 
significantly associated with exacerbation risk with the 
utilization-based exacerbation definition. One explanation for 
this finding might be that women have more severe COPD 
exacerbations requiring medical care, as recently found by 
Kilic et al.42 The alternative would be that men seek medical 
advice less frequently than women (a cultural explanation). 
In addition, the doctor’s response to their patients’ symptoms 
might differ by the patient sex.
In the multivariate analysis, receiving maintenance 
therapy was independently and significantly associated with 
elevated risk of exacerbation. We interpret this association 
as an expression of disease severity. The patients with the 
most impairing disease are also probably those advised 
to use medication and hence more prone to exacerbation 
due to their grade of disease and not due to the medication 
itself. This view is strengthened by the fact that 80% of the 
hospital samples used maintenance therapy (the group with 
the lowest FEV
1
 and most comorbidities in our dataset) and 
as few as 38% of the population-based COPD cases used 
such medication.
Having undergone influenza vaccination was significantly 
associated with a lower exacerbation risk. This confirms 
previous results from large datasets where prophylactic vac-
cination is proven to reduce acute exacerbations and does not 
provoke exacerbations when administered.43 We could not 
find an association between pneumococcal vaccination and 
exacerbation risk. We believe this is due to the fact that as 
few as 47% of the hospital-based COPD patients and 5% of 
the population-based COPD cases had taken this vaccine, and 
hence, we had no power to evaluate this effect.43
The main strength of our study is that we included both 
a population-based and a hospital-based group of COPD 
patients and that the analyses were performed on both groups 
highlighting the importance of source origin. We included 
two much-used definitions of an exacerbation and performed 
our analyses for these definitions separately on the same 
dataset. To our best knowledge, this has not been done before 
including a population-based sample. The Hokkaido cohort 
included several exacerbation definitions, but no population 
sample nor a control group.8 Additionally, our project was 
prospective and had trained health personnel doing telephone 
interviews at intervals minimizing recall bias.44 The overall 
response rate was high (79%), which enabled us to generalize 
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Some possible weaknesses deserve mentioning. First, 
never-smoking subjects and subjects younger than 40 years 
were excluded. This was to avoid confounding with asthma 
patients and to ensure that potential differences between 
COPD cases and controls could not be explained by distinct 
smoking history. Second, the number of population-recruited 
COPD cases was lower than the number of participants from 
the other two groups and there were fewer with severe and 
very severe airflow limitation in this group. Yet, even in this 
group, there was a significantly increasing exacerbation risk 
with worsening grade of COPD, suggesting sufficient power. 
Third, participants of the current study were recruited from 
the city of Bergen, Western Norway, and eleven surround-
ing municipalities. However, a comparison between national 
Norwegian survey data for individuals older than 40 years 
with patients from the original cohort study that EconCOPD 
recruited from showed no discrepancy.45 Finally, with our 
given sample size, the current analyses might have been prone 
to type II errors. Nevertheless, we were able to demonstrate 
a clear effect of the main explanatory variable (population) 
on the outcome.
Our results can help clinicians in identifying groups of 
patients at high risk of exacerbation who can benefit from 
better prevention of modifiable predictors and early onset of 
treatment, which may reduce morbidity and mortality.
We have found that COPD patients from a population 
sample exacerbate 2.0–2.5 times less frequently than hospital-
based COPD patients, depending on the definition used. Apart 
from belonging to the hospital sample, increasing COPD 
severity gives significantly higher risk of exacerbation.
Conclusion
Our results, combined with previous findings,46,47 demon-
strate that several studies on exacerbation rate use selected 
populations6,14,38 and hence suggest exaggerated rates of 
exacerbation, which in turn overstate the effect of medication. 
Thus, our finding implies that any study with AECOPD as 
the primary outcome should recruit from population-based 
samples and, if not possible, explicitly state from which 
population patients are recruited. Furthermore, implications 
of the chosen definition of AECOPD should be discussed.
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Table S1 number of events of exacerbations of respiratory symptoms in population-recruited cases by sex, age, smoking status, 
education, and FeV1% predicted
Variable Resource-defined 
exacerbations




Kwallis with ties, 
P-values
age (yrs), mean (sD) 0.0085 0.3965
,50 1.3 (1.5) 2.3 (2.9)
50–65 0.2 (0.6) 3.9 (7.8)
.65 0.5 (1.1) 1.5 (2.9)
sex, mean (sD) 0.1015 0.0910
Female 0.6 (1.2) 4.0 (5.4)
Male 0.2 (0.8) 2.3 (6.5)
smoking status, mean (sD) 0.2638 0.0939
Current 0.4 (0.7) 3.3 (8.1)
ex-smoker 0.4 (1.1) 2.4 (3.9)
Pack-years, mean (sD) 0.7691 0.0959
,20 0.3 (0.6) 1.8 (3.4)
20–40 0.4 (1.0) 4.1 (8.2)
.40 0.5 (1.3) 2.2 (5.0)
education, mean (sD) 0.0254 0.8132
Primary 0.2 (0.5) 3.2 (8.3)
secondary 0.8 (1.4) 2.9 (4.8)
University 0.1 (0.2) 2.3 (3.7)
FeV1% predicted, mean (sD) 0.0437 0.7227
50–80 0.2 (0.6) 2.9 (6.6)
30–50 0.8 (1.2) 2.4 (3.2)
,30 2.3 (2.6) 2.5 (3.1)
number of comorbid conditions, 
mean (sD)
0.4162 0.2860
0 0.3 (0.6) 3.9 (9.2)
1 0.4 (1.1) 2.0 (3.7)
2 0.2 (0.4) 1.2 (1.8)
$3 0.9 (1.4) 4.3 (5.0)
Maintenance therapy, mean (sD) 0.0008 0.0008
Yes 0.7 (1.2) 4.6 (8.0)
no 0.1 (0.2) 1.1 (2.4)
Influenza vaccination, mean (SD) 0.7422 0.2584
Yes 0.5 (1.2) 2.3 (3.4)
no 0.3 (0.8) 3.2 (7.3)
Pneumococcal vaccination,  
mean (sD)
0.8876 0.0457
Yes 0.3 (0.5) 5.3 (4.3)
no 0.4 (1.0) 2.7 (6.3)
BMI, mean (sD) 0.0007 0.1241
Underweight 2.7 (1.5) 8.7 (8.6)
normal range 0.3 (0.8) 4.1 (8.9)
Overweight 0.3 (0.8) 1.7 (2.9)
Notes: Exacerbations are defined by increased consumption of resources or by symptoms (Anthonisen criteria). The number of events is given as mean (SD).
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Incidence of COPD exacerbations: outcome definition and population
Table S2 number of events of exacerbations of respiratory symptoms in hospital-recruited cases by sex, age, smoking status, 
education, and FeV1% predicted
Variable Resource-defined 
exacerbations




Kwallis with ties, 
P-values
age (yrs), mean (sD) 0.3343 0.0370
,50 1.3 (1.3) 6.5 (5.1)
50–65 1.1 (1.2) 7.1 (6.4)
.65 0.9 (1.2) 5.0 (5.9)
sex, mean (sD) 0.0537 0.0920
Female 1.2 (1.3) 6.4 (6.0)
Male 0.8 (1.0) 5.5 (6.3)
smoking status, mean (sD) 0.0539 0.0489
Current 0.8 (1.0) 4.9 (5.7)
ex-smoker 1.1 (1.2) 6.4 (6.3)
Pack-years, mean (sD) 0.8827 0.8142
,20 1.0 (1.3) 5.8 (6.3)
20–40 1.0 (1.2) 5.9 (5.9)
.40 1.0 (1.1) 5.8 (6.5)
education, mean (sD) 0.2856 0.3174
Primary 1.0 (1.3) 5.5 (5.9)
secondary 1.0 (1.1) 5.9 (6.5)
University 1.2 (1.1) 6.8 (5.7)
FeV1% predicted, mean (sD) 0.001 0.1161
50–80 0.7 (1.1) 5.2 (6.0)
30–50 1.1 (1.1) 6.2 (5.5)
,30 1.7 (1.2) 7.1 (7.7)
number of comorbid conditions, 
mean (sD)
0.8516 0.7727
0 0.9 (1.0) 6.0 (6.3)
1 1.1 (1.1) 5.7 (6.4)
2 1.1 (1.5) 5.4 (6.3)
$3 1.0 (1.1) 6.1 (5.8)
Maintenance therapy, mean (sD) 0.0006 0.0006
Yes 1.1 (1.2) 6.2 (6.2)
no 0.3 (0.4) 3.1 (5.5)
Influenza vaccination, mean (SD) 0.2728 0.7331
Yes 1.0 (1.1) 5.5 (8.6)
no 0.9 (1.3) 6.7 (7.4)
Pneumococcal vaccination,  
mean (sD)
0.0002 0.1613
Yes 1.3 (1.2) 6.0 (5.8)
no 0.7 (1.1) 5.7 (6.5)
O2 therapy, mean (sD) 0.0025 0.5706
Yes 1.8 (1.3) 6.2 (6.0)
no 0.9 (1.1) 5.8 (6.2)
BMI, mean (sD) 0.1172 0.8479
Underweight 1.6 (1.3) 5.4 (4.3)
normal range 0.9 (1.2) 5.4 (5.7)
Overweight 1.0 (1.2) 6.2 (6.7)
Notes: Exacerbations are defined by increased consumption of resources or by symptoms (Anthonisen criteria). The number of events are given as mean (SD).
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hospital 4.58 (3.19–6.60)* 1.59 (1.00–2.52)
sex
Male ref ref
Female 1.45 (1.02–2.05)* 1.57 (1.15–2.14)
age, per 10-year increase 1.18 (1.00–1.39)* 0.93 (0.78–1.10)
smoking status
Former ref ref
Current 0.60 (0.42–0.86)* 0.79 (0.57–1.10)
Pack-years, per increase of 10 1.06 (0.98–1.14) –
educational level
Primary ref –
secondary 1.06 (0.71–1.57) –
University 0.75 (0.46–1.25) –
COPD grade
Control ref ref
gOlD II 4.55 (2.57–8.07)* 2.45 (1.22–4.95)
gOlD III 9.03 (5.00–16.31)* 3.43 (1.59–7.38)
gOlD IV 15.52 (8.34–28.86)* 5.67 (2.58–12.48)
Comorbidities, continuous 1.16 (1.04–1.28)* 1.03 (0.94–1.12)
Maintenance therapy
no ref ref
Yes 4.95 (3.45–7.09)* 1.73 (1.11–2.71)
Influenza vaccination
no ref ref
Yes 2.38 (1.69–3.35)* 0.88 (0.60–1.30)
Pneumococcal vaccination
no ref ref
Yes 3.03 (2.17–4.25)* 1.24 (0.85–1.81)
BMI
Underweight and normal 
weight
ref –
Overweight 0.90 (0.64–1.28) –
Notes: *P,0.10. The results are from negative binomial regression models.
Abbreviations: IRR, incidence rate ratio; CI, confidence interval; AECOPD, acute 
exacerbations of COPD; ref, reference; gOlD, global Initiative on Obstructive 
lung Disease; BMI, body mass index.





hospital 3.81 (2.86–5.07)* 1.78 (1.20–2.64)
sex
Male ref ref
Female 1.15 (0.84–1.57) 1.09 (0.81–1.45)
age, per 10-year increase 1.02 (0.87–1.21) 0.71 (0.60–0.83)
smoking status
Former ref ref
Current 0.74 (0.54–1.02) 0.90 (0.67–1.22)
Pack-years, per increase of 10 1.07 (0.99–1.16) –
educational level
Primary ref –
secondary 0.94 (0.66–1.34) –
University 0.78 (0.51–1.21) –
COPD grade
Control ref ref
gOlD II 5.91 (4.12–8.47)* 3.08 (1.96–4.84)
gOlD III 8.00 (5.23–12.22)* 3.45 (1.92–6.18)
gOlD IV 9.15 (5.45–15.38)* 4.00 (2.09–7.66)
Comorbidities, continuous 1.13 (1.03–1.24)* 1.05 (0.97–1.14)
Maintenance therapy
no ref ref
Yes 3.49 (2.62–4.65)* 1.65 (1.15–2.36)
Influenza vaccination
no ref ref
Yes 1.65 (1.21–2.25)* 0.71 (0.50–1.00)
Pneumococcal vaccination
no ref ref
Yes 2.03 (1.43–2.87)* 1.15 (0.78–1.70)
BMI
Underweight and normal 
weight
ref –
Overweight 0.96 (0.70–1.31) –
Notes: *P,0.10. The results are from negative binomial regression models.
Abbreviations: IRR, incidence rate ratio; CI, confidence interval; AECOPD, acute 
exacerbations of COPD; ref, reference; gOlD, global Initiative on Obstructive 
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